Yiheng Capital Management L.P. Takes Position in BioAge Labs, Inc. $BIOA

Yiheng Capital Management L.P. acquired a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) during the second quarter, HoldingsChannel reports. The fund acquired 170,532 shares of the company’s stock, valued at approximately $4,180,000. BioAge Labs makes up approximately 1.4% of Yiheng Capital Management L.P.’s portfolio, making the stock its 16th largest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in BioAge Labs in the 2nd quarter valued at approximately $69,831,000. Jupiter Topco LLC purchased a new stake in shares of BioAge Labs in the 2nd quarter worth about $52,597,000. Janus Henderson Group PLC grew its stake in BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after acquiring an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in BioAge Labs during the 4th quarter valued at about $13,892,000. Finally, Walleye Capital LLC acquired a new position in BioAge Labs during the second quarter worth about $8,686,000.

BioAge Labs Stock Performance

Shares of BIOA opened at $9.65 on Monday. BioAge Labs, Inc. has a fifty-two week low of $4.55 and a fifty-two week high of $25.95. The company has a market capitalization of $442.94 million, a PE ratio of -4.05 and a beta of 0.94. The stock has a fifty day moving average of $17.80 and a two-hundred day moving average of $18.17.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, equities research analysts forecast that BioAge Labs, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BIOA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Needham & Company LLC cut their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a research note on Monday, August 3rd. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Roth Capital restated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a report on Friday, July 31st. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.